Quality of life and survival of patients with β-thalassemia major

Haematologica

Volumn 89, Issue 10, 2004, Pages 1157-1159

  Cao, Antonio ^a  

^a Ist di Neurogenet/Neurofarmacol   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN;

BLOOD TRANSFUSION; CAUSE OF DEATH; DISEASE ASSOCIATION; DISEASE EXACERBATION; EDITORIAL; FEMALE; FERRITIN BLOOD LEVEL; GENETIC COUNSELING; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HUMAN; INFECTION RISK; IRON CHELATION; IRON OVERLOAD; MALE; PATIENT COMPLIANCE; SURVIVAL; SYMPTOMATOLOGY; THALASSEMIA MAJOR;

ADULT; ANIMALS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CAUSE OF DEATH; CHELATION THERAPY; CHILD; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT, NEWBORN; ITALY; LIFE EXPECTANCY; MALE; MICE; PREGNANCY; PREIMPLANTATION DIAGNOSIS; PRENATAL DIAGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 6344265602     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Wolman IJ. Transfusion therapy in Cooley's anemia: growth and health as related to long-range hemoglobin levels, a progress report. Ann N Y Acad Sci 1964;119:736-52.
2. Piomelli S, Danoff SJ, Becker MH, Lipera MJ, Travis SF. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. Ann N Y Acad Sci 1969;165:427-36.
3. Barry M, Flynn DN, Letsky EA, Risdon RA. Long-term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress. Br Med J 1974;1:16.
4. Modell CB and Beck J. Long-term desferrioxamine therapy in thalassemia. Ann N Y Acad Sci 1974;232:201-10.
5. Hussain MA, Green N, Flynn DM, Hussein S, Hoffbrand AV. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet 1976;2:1278-80.
6. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977;297:418-23.
7. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-31.
8. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi Cet al. Survival and causes of death in thalassaemia major. Lancet 1989;8653:27-30.
9. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-8.
10. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
11. Prati D, Maffioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent β-thalassemia. A multicenter study of 117 cases. Haematologica 2004;89:1179-86.
12. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
13. Callea F. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998;339:1710-1.
14. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent β-thalassemia. Blood 2002;100:1566-9.
15. Cazzola M, Beguin Y, Bergamaschi G, Guarnone R, Cerani P, Barella S, et al. Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. Br J Haematol 1999;106:752-5.
16. Wonke B, Wright C and Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1999;106:252.
17. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516.
18. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003; 43:565.
19. th Annual Meeting of the European Society for Clinical Investigation. Eur J Clin Inv 2004;139:39.
20. Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002; 29:305-28.
21. Orofino MG, Argiolu F, Sanna MA, Rosatelli MC,Tuveri T, Scalas MT, et al. Fetal HLA typing in β-thalassemia: implications for haemopoietic stem-cell transplantation. Lancet 2003;362:41-2.
22. Kuliev A, Rechitsky S, Verlinsky O, Ivakhnenko V, Cieslak J, Evsikov S, et al. Birth of healthy children after preimplantation diagnosis of thalassemias. J Assist Reprod Genet 1999;16:207-11.
23. Gaziev J, Lucarelli G. Stem cell transplantation for hemoglobinopathies. Curr Opin Pediatr 2003;15:24-31.
24. Grewal SS, Kahn JP, MacMillan M, Ramsay NK, Wagner JE. Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. Blood 2004;103:1147.
25. Verlinsky Y, Rechitsky S, Schoolcraft W, Strom C, Kuliev A. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA 2001;285:3130.
26. May C, Rivella S, Callegari J, Gaensler KM, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 2000; 406:82-6.